Daily aspirin may help fight prostate cancer, but not breast cancer

August 27, 2012 by Alan Mozes, Healthday Reporter in Cancer

Daily aspirin may help fight prostate cancer, but not breast cancer

Studies showed 57% reduction in death risk with first, no benefit with second

(HealthDay)—Two new studies paint a complex portrait of aspirin's impact on cancer risk and mortality, with one suggesting the drug may lower the risk of dying from prostate cancer and the other seeing no significant drop in the risk for developing breast cancer.

"These were different types of studies," explained Dr. Stanley Liauw, author of the prostate and an associate professor in the department of radiation and cellular oncology at the University of Chicago Medical Center. "The breast cancer group was looking at how might affect new formations of cancer, while we looked at how it might inhibit ."

"And we're also talking about different disease sites," he added, "which may involve different pathways. So, it's possible that aspirin might affect these pathways differently."

"But there is some rationale, based on previous research, for why we might expect to see an aspirin benefit," Liauw added. "And for our study looking at prostate we actually saw a pretty dramatic effect."

Both findings are published online Aug. 27 in the .

The team, led by Dr. Xuehong Zhang, an instructor in medicine at Brigham and Women's Hospital in Boston, pointed out that the disease is the most frequently diagnosed cancer among American women.

With previous research suggesting that routine aspirin and/or nonsteroidal anti- (NSAID) use reduced the risk for (some of which was conducted by Zhang's team), the Harvard researchers set out to see whether either might have a similar impact on breast cancer.

Between 1980 and 2008, the team tracked nearly 85,000 , all of whom were working as when the study first launched.

Nearly every two years, the women completed questionnaires on their and lifestyle. All were asked about their routine use of aspirin and/or other NSAIDS.

Over the course of three decades, more than 4,700 of the women developed some form of invasive breast cancer. Yet, Zhang's team found that neither regular aspirin nor other NSAIDs had any significant impact on overall breast cancer risk, regardless of how much they were used.

Meanwhile, Liauw and his team explored the potential benefit of aspirin use among nearly 6,000 men diagnosed with, and undergoing treatment for, .

The men were drawn from 41 different health centers across the United States, and all had undergone either surgery (radical prostatectomy) or radiotherapy.

The team noted that 37 percent of the patients were already taking some type of anticoagulant (aspirin, warfarin (Coumadin), clopidogrel (Plavix), and/or enoxaparin). No aspirin or other anticoagulant was prescribed once the study began.

After more than 10 years of follow-up, the team found that among those taking some type of anticoagulant, the risk of dying from prostate cancer was significantly lower than it was among those not taking one.

Further analysis revealed that most of the benefit came from aspirin use, which Liauw said was responsible for a 57 percent reduction in the risk of prostate cancer death.

Because dosage information was not collected, no conclusions could be drawn about exactly how much aspirin was most beneficial. However, the team noted that the protective effect was strongest among patients with particularly "high-risk" disease.

Both study teams said that more research is needed to confirm their respective findings. And neither study proved a cause-and-effect relationship between aspirin use and its effect on cancer.

"So, at this point, this is just hypothesis-generating," Liauw said. "It may be true, but it needs to be tested more formally."

Zhang added that although aspirin showed little benefit with respect to breast cancer risk, he doesn't see any cancer-related downside to their long-term use. However, for women seeking to reduce their breast cancer risk, "the best strategies remain to maintain an ideal weight, exercise, avoid long-term use of postmenopausal hormones, and minimize alcohol intake," he noted.

Two experts who wrote an accompanying editorial in the journal suggested that aspirin might make a difference among very specific subgroups of people.

"When looking at aspirin's impact on breast , looking at all-comers and including all sorts of people who take anti-inflammatory drugs for all sorts of reasons might miss the kernel," said editorial lead author Dr. Clifford Hudis, chief of the medicine service at Memorial Sloan-Kettering Cancer Center, in New York City. "That is to say that there may very well be a subset of people for whom taking aspirin can be of protective benefit "

"But," he added, "the answer always is and remains that you should talk to your doctor about this before deciding to take or not take anything, including aspirin, because none of these studies prove anything definitively one way or another."

Editorial co-author Dr. Andrew Dannenberg, director of the Weill Cornell Cancer Center, agreed.

"It continues to seem to me that aspirin does have a use for reducing the risk for certain cancers," he said. "However, aspirin also has side effects—peptic ulcer disease and hemorrhagic stroke, which are real diseases. And therefore I'm still reluctant at this time to make specific recommendations that people take aspirin for the prevention for cancer. And I believe that prospective trials that better define dose and duration are required before anyone should make definitive recommendations for the use of aspirin in this context."

More information: For more on aspirin and cancer, visit the U.S. National Cancer Institute.

Journal reference: Journal of Clinical Oncology search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 2 hours ago | popularity not rated yet | comments 0

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Cancer created 3 hours ago | popularity not rated yet | comments 0

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...

Cancer created 3 hours ago | popularity not rated yet | comments 0

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 5 hours ago | popularity not rated yet | comments 0

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Cancer created 7 hours ago | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.